Find Clinical Trials & Studies

Visit the Research & Education Institute

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy

I'm Interested!

Please call
1-866-373-1464

A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-103, a Nectin4/Trop2 ADC, as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Sex: Any
Age: Adult (18 - 64), Older Adult (65+)
Accepting Healthy People: No
Type: Interventional / Therapeutic
Trial Phase: Phase I
Conditions Being Studied: Cancer - Solid Tumor, Cancer - Urethral

Study Purpose

This study, the first clinical trial of AVZO-103, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-103 when administered intravenously as a monotherapy and in combination therapy to patients with locally advanced or metastatic urothelial cancer or other solid tumors.

Principal Investigator
Jason Brown MD PhD

Department/Division
Cancer (Any Solid Tumor)

UH IRB: STUDY20260604
StudyID: AVZO1Y26
ClinicalTrials.gov: NCT07193511

I'm Interested!

Please call
1-866-373-1464

Questions or concerns? We're here to help.

Non-cancer Trials: 1-833-78TRIAL or Contact Us Online

Cancer Trials: 1-866-373-1464